Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

LXR as a novel antithrombotic target.

Spyridon M, Moraes LA, Jones CI, Sage T, Sasikumar P, Bucci G, Gibbins JM.

Blood. 2011 May 26;117(21):5751-61. doi: 10.1182/blood-2010-09-306142. Epub 2011 Mar 16.

2.

Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.

Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):279-84. doi: 10.1161/ATVBAHA.113.302781. Epub 2013 Dec 5.

3.

A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.

Blaschke F, Takata Y, Caglayan E, Collins A, Tontonoz P, Hsueh WA, Tangirala RK.

Circ Res. 2006 Dec 8;99(12):e88-99. Epub 2006 Nov 16.

4.

Liver X receptors (LXR) as therapeutic targets in dyslipidemia.

Bełtowski J.

Cardiovasc Ther. 2008 Winter;26(4):297-316. doi: 10.1111/j.1755-5922.2008.00062.x. Review.

PMID:
19035881
5.

Liver X receptor agonists decrease ENaC-mediated sodium transport in collecting duct cells.

Soodvilai S, Jia Z, Fongsupa S, Chatsudthipong V, Yang T.

Am J Physiol Renal Physiol. 2012 Dec 15;303(12):F1610-6. doi: 10.1152/ajprenal.00283.2012. Epub 2012 Oct 17.

6.

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets.

Unsworth AJ, Bye AP, Tannetta DS, Desborough MJR, Kriek N, Sage T, Allan HE, Crescente M, Yaqoob P, Warner TD, Jones CI, Gibbins JM.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1482-1493. doi: 10.1161/ATVBAHA.117.309135. Epub 2017 Jun 15.

7.

Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.

Briand O, Touche V, Colin S, Brufau G, Davalos A, Schonewille M, Bovenga F, Carrière V, de Boer JF, Dugardin C, Riveau B, Clavey V, Tailleux A, Moschetta A, Lasunción MA, Groen AK, Staels B, Lestavel S.

Gastroenterology. 2016 Mar;150(3):650-8. doi: 10.1053/j.gastro.2015.11.015. Epub 2015 Nov 18.

PMID:
26602218
8.

Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.

Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F, Primo L, Hirsch E, Bussolino F, Morello F.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2280-8. doi: 10.1161/ATVBAHA.112.250621. Epub 2012 Jun 21.

9.

Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.

Tsui KH, Chung LC, Feng TH, Lee TY, Chang PL, Chen WT, Juang HH.

Prostate. 2015 May;75(6):603-15. doi: 10.1002/pros.22944. Epub 2015 Jan 5.

PMID:
25560459
10.

Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.

Kim HJ, Yoon KA, Yoon HJ, Hong JM, Lee MJ, Lee IK, Kim SY.

J Leukoc Biol. 2013 Jul;94(1):99-107. doi: 10.1189/jlb.1112601. Epub 2013 May 8.

PMID:
23657115
11.

The medicinal chemistry of liver X receptor (LXR) modulators.

Tice CM, Noto PB, Fan KY, Zhuang L, Lala DS, Singh SB.

J Med Chem. 2014 Sep 11;57(17):7182-205. doi: 10.1021/jm500442z. Epub 2014 May 28.

PMID:
24832115
12.

Lxr regulates lipid metabolic and visual perception pathways during zebrafish development.

Pinto CL, Kalasekar SM, McCollum CW, Riu A, Jonsson P, Lopez J, Swindell EC, Bouhlatouf A, Balaguer P, Bondesson M, Gustafsson JÅ.

Mol Cell Endocrinol. 2016 Jan 5;419:29-43. doi: 10.1016/j.mce.2015.09.030. Epub 2015 Sep 30.

13.

Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.

Kim KH, Lee GY, Kim JI, Ham M, Won Lee J, Kim JB.

J Lipid Res. 2010 Dec;51(12):3425-33. doi: 10.1194/jlr.M007989. Epub 2010 Sep 16.

14.

Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.

Kiss E, Popovic Z, Bedke J, Wang S, Bonrouhi M, Gretz N, Stettner P, Teupser D, Thiery J, Porubsky S, Adams J, Gröne HJ.

Am J Pathol. 2011 Jul;179(1):92-103. doi: 10.1016/j.ajpath.2011.03.019. Epub 2011 May 5.

15.

Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.

Moraes LA, Spyridon M, Kaiser WJ, Jones CI, Sage T, Atherton RE, Gibbins JM.

J Thromb Haemost. 2010 Mar;8(3):577-87. doi: 10.1111/j.1538-7836.2009.03732.x. Epub 2009 Dec 21.

16.

Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.

Morales JR, Ballesteros I, Deniz JM, Hurtado O, Vivancos J, Nombela F, Lizasoain I, Castrillo A, Moro MA.

Circulation. 2008 Sep 30;118(14):1450-9. doi: 10.1161/CIRCULATIONAHA.108.782300. Epub 2008 Sep 15.

17.
18.

The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions.

Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P.

Mol Cell Biol. 2003 Mar;23(6):2182-91.

19.

Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.

Zhang XQ, Even-Or O, Xu X, van Rosmalen M, Lim L, Gadde S, Farokhzad OC, Fisher EA.

Adv Healthc Mater. 2015 Jan 28;4(2):228-36. doi: 10.1002/adhm.201400337. Epub 2014 Aug 22.

20.

Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.

Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, Kappert K, Nakayama KI, Collins AR, Fleck E, Hsueh WA, Law RE, Bruemmer D.

Circ Res. 2004 Dec 10;95(12):e110-23. Epub 2004 Nov 11.

Supplemental Content

Support Center